ArticleCancer science2007
Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis.
Article in Cancer science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 58 citations in OpenAlex.
- Disruption of the ∆40p53/miR-4671-5p/SGSH axis results in intra-S-phase arrest and poor cancer prognosis.The FEBS journal · 2026Article
- Review
- TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions.Hematological oncology · 2025Review
- A Novel Mechanism of the p53 Isoform Δ40p53α in Regulating Collagen III Expression in TGFβ1-Induced LX-2 Human Hepatic Stellate Cells.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance.Cell death & disease · 2024Review
- p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment.Cancers · 2023Review
- The "LINC" between Δ40p53-miRNA Axis in the Regulation of Cellular Homeostasis.Molecular and cellular biology · 2023Article
- p53 and Its Isoforms in Renal Cell Carcinoma-Do They Matter?Biomedicines · 2022Review
- Effect of p53 and its N-terminally truncated isoform, Δ40p53, on breast cancer migration and invasion.Molecular oncology · 2022Article
- Review
- Review
- p53-PHLDA3-Akt Network: The Key Regulators of Neuroendocrine Tumorigenesis.International journal of molecular sciences · 2020Review
- Review
- Identification and characterization of the binding sequences and target genes of p53 lacking the 1st transactivation domain.Cancer science · 2020Article
- Expression Analysis ofCancer management and research · 2020Article
- p53 and its isoforms in DNA double-stranded break repair.Journal of Zhejiang University. Science. B · 2019Review
- PHLDA1, another PHLDA family protein that inhibits Akt.Cancer science · 2018Article
- p53 Isoforms and Their Implications in Cancer.Cancers · 2018Review
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.Nature reviews. Clinical oncology · 2018Review
- A vicious partnership between AKT and PHLDA3 to facilitate neuroendocrine tumors.Cancer science · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The p53 protein exerts its tumor suppressive function mainly by acting as a transcription activator. Two transactivation domains (TADs) located at the amino-terminus of p53 are required for transcription activation, and the activity of TADs is tightly regulated by post-translational modifications, such as phosphorylation. We attempted to dissect the functions of the two TADs and phosphorylation within the TADs by analyzing p53 target genes induced by full-length p53 (FL-p53), N-terminally deleted p53 isoform lacking the first TAD (Delta1stTAD) and p53 carrying point mutations at all serine residues within the two TADs (TAD-S/A). By performing a comprehensive survey by employing microarray expression analysis, the induction of target genes by FL-p53, Delta1stTAD and TAD-S/A was analyzed. All p53s showed different target gene induction patterns, suggesting the importance of the two TADs and phosphorylation within the TADs in target gene induction. Although Delta1stTAD showed a marked decrease in the ability to induce genes induced by FL-p53, Delta1stTAD induced many apoptosis-related genes that were not induced by FL-p53, suggesting the roles of these Delta1stTAD-induced genes in Delta1stTAD-dependent apoptosis. Approximately 80% of genes induced by FL-p53 were not induced by TAD-S/A, including 29 previously reported p53 target genes such as Hdm2 and Bax, emphasizing the importance of phosphorylation within the TADs. These results demonstrate the significance of the regulation and differential roles of the N-terminal TADs in p53 transcriptional activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.